(Q50981985)

English

Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.

scientific article published on 28 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

1 reference

based on heuristic

inferred from title

endometrial carcinoma

1 reference

based on heuristic

inferred from title

Diether Lambrechts

5

object named as

Diether Lambrechts

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

Frédéric Amant

6

object named as

Frédéric Amant

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

author name string

Stefanie Schrauwen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Jeroen Depreeuw

2

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Lieve Coenegrachts

3

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Els Hermans

4

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

language of work or name

0 references

publication date

28 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

138

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

1

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

165-173

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Hormonal treatment of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Markers for individualised therapy in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

PI3K inhibitors for cancer treatment: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.028

7 January 2021

Identifiers

10.1016/J.YGYNO.2015.04.028

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 March 2018

http://europepmc.org/abstract/MED/25933683

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50981985&oldid=1774228250"